myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens

John Brennan, Theresa O'Connor, Robert W. Makuch, Alfreda M. Simmons, Edward Russell, R. Ilona Linnoila, Ruby M. Phelps, Adi F. Gazdar, Daniel C. Ihde, Bruce E. Johnson

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

We studied 107 specimens (38 tumors and 69 tumor cell lines) from 90 patients with small cell lung cancer to determine the characteristics and clinical situations of patients from whom tumor cell lines could be established and the myc family DNA copy number. The proportion of extensive stage small cell lung cancer patients from whom a tumor cell line could be established prior to the initiation of therapy increased during the 10 years of the study (P < 0.001). Amplification of one of the myc family genes occurred in 3 of 40 (8%) of the untreated patient specimens compared to 19 of 67 (28%) of the treated patient specimens (P = 0.01). The myc family DNA amplification occurred in 17 of 54 (31%) of the specimens from patients treated with cyclophosphamide-based combinations and 2 of 13 (15%) of the specimens from patients treated with etoposide/cisplatin (P = 0.25). Both tumors and tumor cell lines were obtained from 17 patients with small cell lung cancer and the myc family DNA copy number was similar in 16 of the 17 patients. We conclude that: (a) myc family DNA amplification occurs more commonly in specimens from treated than untreated patients; (b) there are no prominent differences in the frequency of amplification following treatment with different chemotherapy regimens; and (c) myc family DNA amplification is similar in tumors and tumor cell lines from the same patients.

Original languageEnglish (US)
Pages (from-to)1708-1712
Number of pages5
JournalCancer Research
Volume51
Issue number6
StatePublished - Mar 15 1991

Fingerprint

Small Cell Lung Carcinoma
Combination Drug Therapy
Tumor Cell Line
DNA
Neoplasms
myc Genes
Etoposide
Cyclophosphamide
Cisplatin
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. / Brennan, John; O'Connor, Theresa; Makuch, Robert W.; Simmons, Alfreda M.; Russell, Edward; Linnoila, R. Ilona; Phelps, Ruby M.; Gazdar, Adi F.; Ihde, Daniel C.; Johnson, Bruce E.

In: Cancer Research, Vol. 51, No. 6, 15.03.1991, p. 1708-1712.

Research output: Contribution to journalArticle

Brennan, J, O'Connor, T, Makuch, RW, Simmons, AM, Russell, E, Linnoila, RI, Phelps, RM, Gazdar, AF, Ihde, DC & Johnson, BE 1991, 'myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens', Cancer Research, vol. 51, no. 6, pp. 1708-1712.
Brennan, John ; O'Connor, Theresa ; Makuch, Robert W. ; Simmons, Alfreda M. ; Russell, Edward ; Linnoila, R. Ilona ; Phelps, Ruby M. ; Gazdar, Adi F. ; Ihde, Daniel C. ; Johnson, Bruce E. / myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. In: Cancer Research. 1991 ; Vol. 51, No. 6. pp. 1708-1712.
@article{e035b0afdc164d2a91cbcfc2f56632ad,
title = "myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens",
abstract = "We studied 107 specimens (38 tumors and 69 tumor cell lines) from 90 patients with small cell lung cancer to determine the characteristics and clinical situations of patients from whom tumor cell lines could be established and the myc family DNA copy number. The proportion of extensive stage small cell lung cancer patients from whom a tumor cell line could be established prior to the initiation of therapy increased during the 10 years of the study (P < 0.001). Amplification of one of the myc family genes occurred in 3 of 40 (8{\%}) of the untreated patient specimens compared to 19 of 67 (28{\%}) of the treated patient specimens (P = 0.01). The myc family DNA amplification occurred in 17 of 54 (31{\%}) of the specimens from patients treated with cyclophosphamide-based combinations and 2 of 13 (15{\%}) of the specimens from patients treated with etoposide/cisplatin (P = 0.25). Both tumors and tumor cell lines were obtained from 17 patients with small cell lung cancer and the myc family DNA copy number was similar in 16 of the 17 patients. We conclude that: (a) myc family DNA amplification occurs more commonly in specimens from treated than untreated patients; (b) there are no prominent differences in the frequency of amplification following treatment with different chemotherapy regimens; and (c) myc family DNA amplification is similar in tumors and tumor cell lines from the same patients.",
author = "John Brennan and Theresa O'Connor and Makuch, {Robert W.} and Simmons, {Alfreda M.} and Edward Russell and Linnoila, {R. Ilona} and Phelps, {Ruby M.} and Gazdar, {Adi F.} and Ihde, {Daniel C.} and Johnson, {Bruce E.}",
year = "1991",
month = "3",
day = "15",
language = "English (US)",
volume = "51",
pages = "1708--1712",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens

AU - Brennan, John

AU - O'Connor, Theresa

AU - Makuch, Robert W.

AU - Simmons, Alfreda M.

AU - Russell, Edward

AU - Linnoila, R. Ilona

AU - Phelps, Ruby M.

AU - Gazdar, Adi F.

AU - Ihde, Daniel C.

AU - Johnson, Bruce E.

PY - 1991/3/15

Y1 - 1991/3/15

N2 - We studied 107 specimens (38 tumors and 69 tumor cell lines) from 90 patients with small cell lung cancer to determine the characteristics and clinical situations of patients from whom tumor cell lines could be established and the myc family DNA copy number. The proportion of extensive stage small cell lung cancer patients from whom a tumor cell line could be established prior to the initiation of therapy increased during the 10 years of the study (P < 0.001). Amplification of one of the myc family genes occurred in 3 of 40 (8%) of the untreated patient specimens compared to 19 of 67 (28%) of the treated patient specimens (P = 0.01). The myc family DNA amplification occurred in 17 of 54 (31%) of the specimens from patients treated with cyclophosphamide-based combinations and 2 of 13 (15%) of the specimens from patients treated with etoposide/cisplatin (P = 0.25). Both tumors and tumor cell lines were obtained from 17 patients with small cell lung cancer and the myc family DNA copy number was similar in 16 of the 17 patients. We conclude that: (a) myc family DNA amplification occurs more commonly in specimens from treated than untreated patients; (b) there are no prominent differences in the frequency of amplification following treatment with different chemotherapy regimens; and (c) myc family DNA amplification is similar in tumors and tumor cell lines from the same patients.

AB - We studied 107 specimens (38 tumors and 69 tumor cell lines) from 90 patients with small cell lung cancer to determine the characteristics and clinical situations of patients from whom tumor cell lines could be established and the myc family DNA copy number. The proportion of extensive stage small cell lung cancer patients from whom a tumor cell line could be established prior to the initiation of therapy increased during the 10 years of the study (P < 0.001). Amplification of one of the myc family genes occurred in 3 of 40 (8%) of the untreated patient specimens compared to 19 of 67 (28%) of the treated patient specimens (P = 0.01). The myc family DNA amplification occurred in 17 of 54 (31%) of the specimens from patients treated with cyclophosphamide-based combinations and 2 of 13 (15%) of the specimens from patients treated with etoposide/cisplatin (P = 0.25). Both tumors and tumor cell lines were obtained from 17 patients with small cell lung cancer and the myc family DNA copy number was similar in 16 of the 17 patients. We conclude that: (a) myc family DNA amplification occurs more commonly in specimens from treated than untreated patients; (b) there are no prominent differences in the frequency of amplification following treatment with different chemotherapy regimens; and (c) myc family DNA amplification is similar in tumors and tumor cell lines from the same patients.

UR - http://www.scopus.com/inward/record.url?scp=0025907433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025907433&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 1708

EP - 1712

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -